Evaluation of omalizumab at certain time intervals in patients with chronic spontaneous idiopathic urticaria

Simple item page
dc.contributor.authorKutlu, Ömeren_US
dc.contributor.authorKaraarslan, Enginen_US
dc.contributor.authorKaraosmanoğlul, Nerminen_US
dc.contributor.authorEkşioğlu, Hatice Meralen_US
dc.date.accessioned2020-11-18T10:10:36Z
dc.date.available2020-11-18T10:10:36Z
dc.date.issued2019-12
dc.description.abstractBackground:In this study, we aimed to evaluate the response of patient treated with omalizumab at certain time intervals through 6 months with pruritus visual analog scale, urticaria activity score and quality of life indexes. Methods:The study was performed on ten patients diagnosed with chronic idiopathic spontaneous urticaria.The disease was assessed by the Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL) and Dermatology Life Quality Index(DLQI) for every 2 weeks while was assessed by Urticaria Activity Score (UAS-7) and Pruritus Visual Analog Scale (PVAS) for once a week during the 6-month treatment period.Statistical significance was evaluated using the Mann-WhitneyUtest in SPSS 20.Results:Pre-treatment values of the DLQI, CU-Q2oL, UAS-7, and PVAS was statistically higher than post-treatment values of these indexes (p<0.05). The mean DLQI/ CU-Q2oLvalue of the patients beforetreatment was 17±6.09/ 52.87±22.07 while it was 19.4±16.36 at the end of 2nd-week post-injection per month, and was 21.85±16.56 at the end of 4nd-week post-injection per month during 6-months following. Statistically, PVAS score at the 4thweek was higher than 2nd and 3rdweeks(p<0.042, p<0.007).Conclusions:In this study, it was detected that omalizumab had a significant effect on DLQI, CU-Q2oL, UAS-7, PVAS scores in CISU. It can be concluded that significant increase of PVAS score at 4th week compared to scores at 2nd and 3rd week may necessitate the use of omalizumab combined with antihistamines at 4th week of the treatmenten_US
dc.identifier.affiliationsDepartment of Dermatology and Venereology, Kayseri Develi State Hospital, Kayserien_US
dc.identifier.affiliationsMardin Nusaybin State Hospital, Mardinen_US
dc.identifier.affiliationsAnkara Training and Research Hospital, Ankara, Turkeyen_US
dc.identifier.affiliationsAnkara Training and Research Hospital, Ankara, Turkeyen_US
dc.identifier.citationKutlu Ömer, Karaarslan Engin, Karaosmanoğlul Nermin, Ekşioğlu Hatice Meral. Evaluation of omalizumab at certain time intervals in patients with chronic spontaneous idiopathic urticaria. International Journal of Scientific Reports. 2019 Dec; 5(12): 351-354en_US
dc.identifier.issn2454-2456
dc.identifier.issn2454-2164
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/213986
dc.languageenen_US
dc.publisherMedip Academyen_US
dc.relation.issuenumber12en_US
dc.relation.volume5en_US
dc.source.urihttps://dx.doi.org//10.18203/issn.2454-2156.IntJSciRep20195299en_US
dc.subjectLife qualityen_US
dc.subjectOmalizumaben_US
dc.subjectPruritus visual analog scaleen_US
dc.subjectUrticariaen_US
dc.titleEvaluation of omalizumab at certain time intervals in patients with chronic spontaneous idiopathic urticariaen_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
ijsr2019v5n12p351.pdf
Size:
456.03 KB
Format:
Adobe Portable Document Format
Download
Collections
International Journal of Scientific Reports